clinical dataLeyden Labs reports first human data for intranasal flu prevention antibodyLeyden Labs has released new early-stage data on its intranasal antibody program for influenza prevention, adding phase 1 human safety results to previously disclosed animal studies. more ➔
chokniti - Adobe StockRadiopharmacyPentixapharm: positive Phase II data on Pentixafor PET diagnostics pave way for radiotherapeuticsPentixapharm Holding AG published new clinical Phase II data on its radiodiagnostic agent [68Ga]Ga-Pentixafor in early February. As the Berlin-based company reported, the results published in the Journal … more ➔
GenomicsPharosAI partners with 10x Genomics on spatial cancer data backed by £18.9 millionPharosAI, a U.K. cancer research consortium bringing together King’s College London, Queen Mary University of London, Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust and Barts … more ➔
Clinical trialsCereno widens clinical program as competition heats up in lung diseaseSwedish biotech Cereno Scientific today announced the expansion of its clinical development program for its investigational small-molecule therapy, CS014, targeting rare lung diseases. more ➔
RestructuringPoxel takes first step in recovery plan with €5 million equity lineFrench biotech Poxel is trying to stabilise its business after judicial reorganisation, with its court-approved recovery plan now moving into the execution phase. The Lyon-based company, which has spent … more ➔
Sartorius AGSartoriusSartorius returns to a path of profitable growth in 2025The Göttingen-based life science group Sartorius AG closed the 2025 financial year, based on preliminary figures, with a marked increase in revenue and earnings. Group sales grew by 7.6% at constant … more ➔
Licence agreementKahimmune launches and secures exclusive license for dark-genome cancer vaccine platformNewly formed French biotech Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay, securing rights to a technology platform designed to identify … more ➔
Photo: Carolina Garcia Tavizon, via Unsplash NeuroscienceOrigami and Ipsen join forces on protein degradation in neuroscienceFrench biopharmaceutical company Ipsen has entered a global collaboration and option agreement with San Diego-based biotech Origami Therapeutics to advance a small-molecule protein degrader program targeting … more ➔
©FabienMalotYearly results Sanofi ends 2025 on a high, but trims R&D prioritiesParis-based drugmaker Sanofi closed 2025 with strong growth and upbeat guidance, but its latest results also reveal sharp pipeline cuts that underline a tougher phase for R&D choices. more ➔
Lonza GroupCDMOCDMOs dominate the headlines – and Lonza delivers a clear message of strengthCDMOs are currently setting the agenda across the industry. Alongside peers such as Vetter, Lonza has now delivered a clear statement of intent: strong results, sharper focus and an even more determined … more ➔
chokniti - Adobe Stock
Sartorius AG
Photo: Carolina Garcia Tavizon, via Unsplash 
©FabienMalot
Lonza Group